文献速递神经创伤神经重症

基于多变量分析的创伤性脑损伤患者颅内血肿扩大风险预测模型

Multivariable Analysis-Based Risk Prediction Model for Intracranial Hematoma Expansion in Traumatic Brain Injury Patients.
PubMed 文献 · World Neurosurg · 2026-01-27

本研究基于263例创伤性脑挫伤患者数据,构建并验证了血肿扩大(HE)的临床预测模型。多变量分析确定硬膜下血肿、纤维蛋白降解产物>30 mg/L、蛛网膜下腔出血、额叶损伤和GCS<13为独立预测因子。模型在训练集和验证集的AUC分别为0.937和0.888,校准良好,风险分层可有效区分低、中、高风险组。

要点

  • 硬膜下血肿、FDP>30 mg/L、蛛网膜下腔出血、额叶损伤和GCS<13是HE的独立预测因子。
  • 预测模型在训练集和验证集的AUC分别为0.937和0.888,校准良好。
  • 风险分层将患者分为低危(0-2分)、中危(3-4分)和高危(5-6分),HE率分别为11%、48%和87%。

核心结论

  • 该预测模型对创伤性脑挫伤患者血肿扩大具有优秀的区分度和校准度,为个体化监测和治疗提供量化依据。

研究设计与样本

  • 患者按7:3随机分为训练集(n=184)和验证集(n=79),另设88例补充验证集。

主要发现

  • 263例患者中血肿扩大发生率为60%(157/263)。
  • 多变量分析确定5个独立预测因子:硬膜下血肿(OR=7.71,95%CI:4.06-14.65)、纤维蛋白降解产物>30 mg/L(OR=3.46,95%CI:1.80-6.63)、蛛网膜下腔出血(OR=3.04,95%CI:1.50-6.17)、额叶损伤(OR=2.52,95%CI:1.30-4.89)、GCS<13(OR=2.50,95%CI:1.11-5.60),均P<0.05。
  • 训练集AUC为0.937(95%CI:0.95-0.99),验证集AUC为0.888(95%CI:0.82-0.95)。
  • Hosmer-Lemeshow检验显示校准良好(训练集P=0.702,验证集P=0.944)。
  • 补充验证集中低危(0-2分)、中危(3-4分)、高危(5-6分)组的血肿扩大率分别为11%、48%、87%(P<0.001)。

关键数值与推荐

  • 血肿扩大定义为伤后24小时内复查头颅CT显示血肿体积增加>33%或绝对增加>6 mL,或出现新发出血灶。
  • 风险评分:低危0-2分,中危3-4分,高危5-6分。

临床怎么用

  • 该评分系统简单实用,可用于早期识别创伤性脑挫伤后血肿扩大高危患者,指导个体化监测和治疗策略。

局限性

  • 单中心回顾性研究,样本量有限,需多中心前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop and validate a clinical prediction model for hematoma expansion (HE) in traumatic brain contusion (TBC) patients, providing a quantitative tool for early identification of high-risk patients. METHODS: A single-center retrospective cohort study was conducted, collecting clinical data from 263 TBC patients admitted to the Department of Neurosurgery at Lianyungang First People's Hospital between July 2022 and December 2024. Patients were randomly divided into training (n = 184) and validation (n = 79) cohorts at a 7:3 ratio, with an additional 88 patients serving as a supplementary validation cohort. Demographic characteristics, clinical presentations, laboratory parameters, and imaging features were collected. HE was defined as >33% increase in hematoma volume or an absolute increase of >6 mL on follow-up cranial computed tomography within 24 hours postinjury, or the emergence of new hemorrhagic lesions. Univariate and multivariate logistic regression analyses were performed to identify independent predictors. Model performance was evaluated using receiver operating characteristic curves, calibration plots, and decision curve analysis. RESULTS: Among 263 TBC patients, HE occurred in 60% (157/263). Univariate analysis identified 9 factors significantly associated with HE. Multivariate analysis determined five independent predictors: subdural hematoma (odds ratio [OR] = 7.71, 95% confidence interval [CI]: 4.06-14.65), fibrin degradation products >30 mg/L (OR = 3.46, 95% CI: 1.80-6.63), subarachnoid hemorrhage (OR = 3.04, 95% CI: 1.50-6.17), frontal lobe injury (OR = 2.52, 95% CI: 1.30-4.89), and Glasgow Coma Scale <13 (OR = 2.50, 95% CI: 1.11-5.60) (all P < 0.05). The prediction model achieved area under the curves of 0.937 (95% CI: 0.95-0.99) and 0.888 (95% CI: 0.82-0.95) in training and validation cohorts, respectively. Hosmer-Lemeshow tests demonstrated good calibration (training cohort P = 0.702, validation cohort P = 0.944). Decision curve analysis confirmed favorable clinical net benefit. Risk stratification classified patients into low-risk (0-2 points), intermediate-risk (3-4 points), and high-risk (5-6 points) groups, with HE rates of 11%, 48%, and 87%, respectively, in the supplementary validation cohort (P < 0.001). CONCLUSIONS: The developed prediction model for HE in TBC patients demonstrates excellent discrimination and calibration, providing quantitative evidence for individualized monitoring and treatment strategies that may improve patient outcomes. This scoring system is simple, practical, and holds promising clinical application potential.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Liu C, Wu R, Yang Y, et al. Multivariable Analysis-Based Risk Prediction Model for Intracranial Hematoma Expansion in Traumatic Brain Injury Patients. World Neurosurg. 2026. PMID: 41611014. doi:10.1016/j.wneu.2026.124823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。